The RUNX family: Developmental regulators in cancer

Nature Reviews Cancer

Volumn 15, Issue 2, 2015, Pages 81-95

  Ito, Yoshiaki ^a   Bae, Suk Chul ^b   Chuang, Linda Shyue Huey ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Chungbuk National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P53; TRANSCRIPTION FACTOR RUNX; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR RUNX3; TRANSCRIPTION FACTOR SIN3A; TRANSFORMING GROWTH FACTOR BETA; ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; CYCLIN DEPENDENT KINASE;

CANCER GROWTH; CANCER LOCALIZATION; CANCER RESEARCH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME ABERRATION; DNA BINDING; DNA DAMAGE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY; DNA METHYLATION; DNA REPAIR; GENETIC TRANSCRIPTION; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; NEOPLASM; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADP-RIBOSYLATION FACTORS; CELL DIFFERENTIATION; CELL PROLIFERATION; CORE BINDING FACTOR ALPHA SUBUNITS; CYCLIN-DEPENDENT KINASES; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; HUMANS; INFLAMMATION; NEOPLASMS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84923118816     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3877     Document Type: Review

References (193)

1. Ito, Y. RUNX genes in development and cancer: Regulation of viral gene expression and the discovery of RUNX family genes. Adv. Cancer Res. 99, 33-76 (2008).
2. Ito, Y. & Miyazono, K. RUNX transcription factors as key targets of TGF-? superfamily signaling. Curr. Opin. Genet. Dev. 13, 43-47 (2003).
3. Ito, K. et al. RUNX3 attenuates ?-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 14, 226-237 (2008).
4. Pratap, J. et al. Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res. 68, 7795-7802 (2008).
5. Hilton, M. J. et al. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nature Med. 14, 306-314 (2008).
6. Huang, H. et al. A Src family kinase-Shp2 axis controls RUNX1 activity in megakaryocyte and T-lymphocyte differentiation. Genes Dev. 26, 1587-1601 (2012).
7. Min, B. et al. Identification of RUNX3 as a component of the MST/Hpo signaling pathway. J. Cell. Physiol. 227, 839-849 (2012).
8. Yagi, R., Chen, L. F., Shigesada, K., Murakami, Y. & Ito, Y. A. WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J. 18, 2551-2562 (1999).
9. Mangan, J. K. & Speck, N. A. RUNX1 mutations in clonal myeloid disorders: From conventional cytogenetics to next generation sequencing, a story 40 years in the making. Crit. Rev. Oncog 16, 77-91 (2011).
10. Pratap, J. et al. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev. 25, 589-600 (2006).
11. Stewart, M. et al. Proviral insertions induce the expression of bone-specific isoforms of PEBP2?A (CBFA1): Evidence for a new myc collaborating oncogene. Proc. Natl Acad. Sci. USA 94, 8646-8651 (1997).
12. Wotton, S. et al. Proviral insertion indicates a dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma. Cancer Res. 62, 7181-7185 (2002).
13. Stewart, M., MacKay, N., Cameron, E. R. & Neil, J. C. The common retroviral insertion locus Dsi1 maps 30 kilobases upstream of the P1 promoter of the murine Runx3/Cbfa3/Aml2 gene. J. Virol. 76, 4364-4369 (2002).
14. Uren, A. G. et al. Large-scale mutagenesis in p19(ARF)-and p53-deficient mice identifies cancer genes and their collaborative networks. Cell 133, 727-741 (2008).
15. Levanon, D. & Groner, Y. Structure and regulated expression of mammalian RUNX genes. Oncogene 23, 4211-4219 (2004). The genomic organization of the three RUNX genes, including intron-exon structures and the positions of the two promoters are shown.
16. Tahirov, T. H. et al. Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBF?. Cell 104, 755-767 (2001).
17. Chuang, L. S., Ito, K. & Ito, Y. RUNX family: Regulation and diversification of roles through interacting proteins. Int. J. Cancer 132, 1260-1271 (2013).
18. Kim, W. Y. et al. Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains. EMBO J. 18, 1609-1620 (1999).
19. Yu, M. et al. Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors. Mol. Cell 45, 330-343 (2012).
20. Guo, H. & Friedman, A. D. Phosphorylation of RUNX1 by cyclin-dependent kinase reduces direct interaction with HDAC1 and HDAC3. J. Biol. Chem. 286, 208-215 (2011).
21. Westendorf, J. J. et al. Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol. Cell. Biol. 22, 7982-7992 (2002).
22. Huang, G. et al. The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations. Blood 118, 6544-6552 (2011).
23. Kitabayashi, I., Aikawa, Y., Nguyen, L. A., Yokoyama, A. & Ohki, M. Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein. EMBO J. 20, 7184-7196 (2001).
24. Aikawa, Y. et al. Roles of HIPK1 and HIPK2 in AML1-and p300-dependent transcription, hematopoiesis and blood vessel formation. EMBO J. 25, 3955-3965 (2006).
25. Wee, H. J., Voon, D. C., Bae, S. C. & Ito, Y. PEBP2-?/CBF-?-dependent phosphorylation of RUNX1 and p300 by HIPK2: Implications for leukemogenesis. Blood 112, 3777-3787 (2008).
26. Tanaka, T. et al. The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability. Mol. Cell. Biol. 16, 3967-3979 (1996).
27. Imai, Y. et al. The corepressor mSin3A regulates phosphorylation-induced activation, intranuclear location, and stability of AML1. Mol. Cell. Biol. 24, 1033-1043 (2004).
28. Bae, S. C. & Lee, Y. H. Phosphorylation, acetylation and ubiquitination: The molecular basis of RUNX regulation. Gene 366, 58-66 (2006).
29. Jin, Y. H. et al. Transforming growth factor-? stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J. Biol. Chem. 279, 29409-29417 (2004).
30. Zhao, X. et al. Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity. Genes Dev. 22, 640-653 (2008).
31. Zhang, L., Fried, F. B., Guo, H. & Friedman, A. D. Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation. Blood 111, 1193-1200 (2008).
32. Strom, D. K. et al. Expression of the AML-1 oncogene shortens the G1 phase of the cell cycle. J. Biol. Chem. 275, 3438-3445 (2000).
33. Shen, R. et al. Cyclin D1-cdk4 induce runx2 ubiquitination and degradation. J. Biol. Chem. 281, 16347-16353 (2006).
34. Biggs, J. R., Peterson, L. F., Zhang, Y., Kraft, A. S. & Zhang, D. E. AML1/RUNX1 phosphorylation by cyclin-dependent kinases regulates the degradation of AML1/RUNX1 by the anaphase-promoting complex. Mol. Cell. Biol. 26, 7420-7429 (2006).
35. Rajgopal, A. et al. Mitotic control of RUNX2 phosphorylation by both CDK1/cyclin B kinase and PP1/PP2A phosphatase in osteoblastic cells. J. Cell Biochem. 100, 1509-1517 (2007).
36. Young, D. W. et al. Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2. Nature 445, 442-446 (2007).
37. Young, D. W. et al. Mitotic retention of gene expression patterns by the cell fate-determining transcription factor Runx2. Proc. Natl Acad. Sci. USA 104, 3189-3194 (2007).
38. Ben-Ami, O. et al. Addiction of t(8;21) and inv(16) acute myeloid leukemia to native RUNX1. Cell Rep. 4, 1131-1143 (2013).
39. Belkina, A. C. & Denis, G. V. BET domain co-regulators in obesity, inflammation and cancer. Nature Rev. Cancer 12, 465-477 (2012).
40. Lee, Y. S. et al. Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma. Cancer Cell 24, 603-616 (2013).
41. Yoshimi, M. et al. Multiple phosphorylation sites are important for RUNX1 activity in early hematopoiesis and T-cell differentiation. Eur. J. Immunol. 42, 1044-1050 (2012).
42. Wang, L. et al. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 333, 765-769 (2011).
43. Kim, W. J. et al. Nicotinamide inhibits growth of carcinogen induced mouse bladder tumor and human bladder tumor xenograft through up-regulation of RUNX3 and p300. J. Urol. 185, 2366-2375 (2011).
44. Song, W. J. et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nature Genet. 23, 166-175 (1999).
45. Matheny, C. J. et al. Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles. EMBO J. 26, 1163-1175 (2007).
46. Mundlos, S. et al. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 89, 773-779 (1997).
47. De Braekeleer, E. et al. RUNX1 translocations and fusion genes in malignant hemopathies. Future Oncol. 7, 77-91 (2011).
48. Miyoshi, H. et al. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc. Natl Acad. Sci. USA 88, 10431-10434 (1991).
49. Sun, X. J. et al. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis. Nature 500, 93-97 (2013).
50. Higuchi, M. et al. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1, 63-74 (2002).
51. Mori, H. et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc. Natl Acad. Sci. USA 99, 8242-8247 (2002).
52. Goyama, S. et al. Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J. Clin. Invest. 123, 3876-3888 (2013).
53. Osato, M. Point mutations in the RUNX1/AML1 gene: Another actor in RUNX leukemia. Oncogene 23, 4284-4296 (2004).
54. Cammenga, J. et al. RUNX1 DNA-binding mutants, associated with minimally differentiated acute myelogenous leukemia, disrupt myeloid differentiation. Cancer Res. 67, 537-545 (2007).
55. Della Gatta, G. et al. Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL. Nature Med. 18, 436-440 (2012).
56. Ellis, M. J. et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486, 353-360 (2012).
57. Banerji, S. et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486, 405-409 (2012). References 56 and 57 identify RUNX1 and CBFB as being significantly mutated in breast cancer, indicating that defective RUNX1 function might have a driver role in solid tumour formation.
58. Kadota, M. et al. Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. PLoS ONE 5, e9201 (2010).
59. Ramaswamy, S., Ross, K. N., Lander, E. S. & Golub, T. R. A molecular signature of metastasis in primary solid tumors. Nature Genet. 33, 49-54 (2003).
60. Harrison, C. J. et al. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): Cytogenetic characterization and outcome. Leukemia 28, 1015-1021 (2013).
61. Osato, M. & Ito, Y. Increased dosage of the RUNX1/AML1 gene: A third mode of RUNX leukemia? Crit. Rev. Eukaryot. Gene Expr 15, 217-228 (2005).
62. Scheitz, C. J., Lee, T. S., McDermitt, D. J. & Tumbar, T. Defining a tissue stem cell-driven Runx1/Stat3 signalling axis in epithelial cancer. EMBO J. 31, 4124-4139 (2012).
63. Planaguma, J. et al. A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma. Cancer Res. 64, 8846-8853 (2004).
64. Lau, C. C. et al. Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer 39, 11-21 (2004).
65. Martin, J. W., Zielenska, M., Stein, G. S., Van Wijnen, A. J. & Squire, J. A. The role of RUNX2 in osteosarcoma oncogenesis. Sarcoma 2011, 282745 (2011).
66. Sadikovic, B. et al. Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. BMC Cancer 10, 202 (2010).
67. Akech, J. et al. Runx2 association with progression of prostate cancer in patients: Mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29, 811-821 (2010).
68. Ezaki, T. et al. Deletion mapping on chromosome 1p in well-differentiated gastric cancer. Br. J. Cancer 73, 424-428 (1996).
69. Schwab, M., Praml, C. & Amler, L. C. Genomic instability in 1p and human malignancies. Genes Chromosomes Cancer 16, 211-229 (1996).
70. Nomoto, S. et al. Frequent allelic imbalance suggests involvement of a tumor suppressor gene at 1p36 in the pathogenesis of human lung cancers. Genes Chromosomes Cancer 28, 342-346 (2000).
71. Matsumoto, H. et al. Allelic imbalance at 1p36 may predict prognosis of chemoradiation therapy for bladder preservation in patients with invasive bladder cancer. Br. J. Cancer 91, 1025-1031 (2004).
72. Bagchi, A. & Mills, A. A. The quest for the 1p36 tumor suppressor. Cancer Res. 68, 2551-2556 (2008).
73. Huang, J., Zhao, Y. L., Li, Y., Fletcher, J. A. & Xiao, S. Genomic and functional evidence for an ARID1A tumor suppressor role. Genes Chromosomes Cancer 46, 745-750 (2007).
74. Chuang, L. S. & Ito, Y. RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene 29, 2605-2615 (2010).
75. Kim, W. J. et al. RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res. 65, 9347-9354 (2005).
76. Kandimalla, R., Van Tilborg, A. A. & Zwarthoff, E. C. DNA methylation-based biomarkers in bladder cancer. Nature Rev. Urol. 10, 327-335 (2013).
77. Wolff, E. M. et al. RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking. Cancer Res. 68, 6208-6214 (2008).
78. Lee, K. S. et al. Runx3 is required for the differentiation of lung epithelial cells and suppression of lung cancer. Oncogene 29, 3349-3361 (2010).
79. Weisenberger, D. J. et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nature Genet. 38, 787-793 (2006).
80. Webber, B. R. et al. DNA methylation of Runx1 regulatory regions correlates with transition from primitive to definitive hematopoietic potential in vitro and in vivo. Blood 122, 2978-2986 (2013).
81. Lau, Q. C. et al. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res. 66, 6512-6520 (2006).
82. Ito, K. et al. RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res. 65, 7743-7750 (2005).
83. Li, Q. L. et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109, 113-124 (2002).
84. Chi, X. Z. et al. RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor ?-activated SMAD. Mol. Cell. Biol. 25, 8097-8107 (2005).
85. Lee, C. W. et al. RUNX3 functions as an oncogene in ovarian cancer. Gynecol. Oncol. 122, 410-417 (2011).
86. Salto-Tellez, M. et al. RUNX3 protein is overexpressed in human basal cell carcinomas. Oncogene 25, 7646-7649 (2006).
87. Nevadunsky, N. S. et al. RUNX3 protein is overexpressed in human epithelial ovarian cancer. Gynecol. Oncol. 112, 325-330 (2009).
88. Tsunematsu, T. et al. RUNX3 has an oncogenic role in head and neck cancer. PLoS ONE 4, e5892 (2009).
89. Bernardin-Fried, F. et al. AML1/RUNX1 increases during G1 to S cell cycle progression independent of cytokine-dependent phosphorylation and induces cyclin D3 gene expression. J. Biol. Chem. 279, 15678-15687 (2004).
90. Galindo, M. et al. The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts. J. Biol. Chem. 280, 20274-20285 (2005).
91. Jacob, B. et al. Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis. Blood 115, 1610-1620 (2010).
92. Ichikawa, M. et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nature Med. 10, 299-304 (2004).
93. Sanda, T. et al. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell 22, 209-221 (2012).
94. Kwiatkowski, N. et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 511, 616-620 (2014).
95. Liu, W. et al. Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J. Cell Biol. 155, 157-166 (2001).
96. Komori, T. Regulation of bone development and extracellular matrix protein genes by RUNX2. Cell Tissue Res. 339, 189-195 (2010).
97. Pratap, J. et al. Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. Cancer Res. 63, 5357-5362 (2003).
98. Calo, E. et al. Rb regulates fate choice and lineage commitment in vivo. Nature 466, 1110-1114 (2010).
99. Thomas, D. M. et al. The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol. Cell 8, 303-316 (2001).
100. Thomas, D. M. et al. Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J. Cell Biol. 167, 925-934 (2004).
101. Won, K. Y., Park, H. R. & Park, Y. K. Prognostic implication of immunohistochemical Runx2 expression in osteosarcoma. Tumori 95, 311-316 (2009).
102. Lengner, C. J. et al. Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J. Cell Biol. 172, 909-921 (2006).
103. Owens, T. W. et al. Runx2 is a novel regulator of mammary epithelial cell fate in development and breast cancer. Cancer Res. 74, 5277-5286 (2014).
104. Collins, A., Littman, D. R. & Taniuchi, I. RUNX proteins in transcription factor networks that regulate T-cell lineage choice. Nature Rev. Immunol. 9, 106-115 (2009).
105. Taniuchi, I. et al. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell 111, 621-633 (2002).
106. Setoguchi, R. et al. Repression of the transcription factor Th-POK by Runx complexes in cytotoxic T cell development. Science 319, 822-825 (2008).
107. Steinke, F. C. et al. TCF-1 and LEF-1 act upstream of Th-POK to promote the CD4+ T cell fate and interact with Runx3 to silence Cd4 in CD8+ T cells. Nature Immunol. 15, 646-656 (2014).
108. Hu, G. & Chen, J. A genome-wide regulatory network identifies key transcription factors for memory CD8+ T-cell development. Nature Commun. 4, 2830 (2013).
109. Vaillant, F., Blyth, K., Andrew, L., Neil, J. C. & Cameron, E. R. Enforced expression of Runx2 perturbs T cell development at a stage coincident with ?-selection. J. Immunol. 169, 2866-2874 (2002).
110. Ito, K. et al. Loss of Runx3 is a key event in inducing precancerous state of the stomach. Gastroenterology 140, 1536-1546 (2011).
111. Drissi, H. et al. Transcriptional autoregulation of the bone related CBFA1/RUNX2 gene. J. Cell. Physiol. 184, 341-350 (2000).
112. Bangsow, C. et al. The RUNX3 gene - sequence, structure and regulated expression. Gene 279, 221-232 (2001).
113. Levanon, D. et al. AML1, AML2, and AML3, the human members of the runt domain gene-family: CDNA structure, expression, and chromosomal localization. Genomics 23, 425-432 (1994).
114. Van Der Deen, M. et al. Genomic promoter occupancy of runt-related transcription factor RUNX2 in osteosarcoma cells identifies genes involved in cell adhesion and motility. J. Biol. Chem. 287, 4503-4517 (2012).
115. Chimge, N. O. & Frenkel, B. The RUNX family in breast cancer: Relationships with estrogen signaling. Oncogene 32, 2121-2130 (2013).
116. Ikushima, H. & Miyazono, K. TGF? signalling: A complex web in cancer progression. Nature Rev. Cancer 10, 415-424 (2010).
117. Hanai, J. et al. Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline C? promoter. J. Biol. Chem. 274, 31577-31582 (1999).
118. Yamamura, Y., Lee, W. L., Inoue, K., Ida, H. & Ito, Y. RUNX3 cooperates with FoxO3a to induce apoptosis in gastric cancer cells. J. Biol. Chem. 281, 5267-5276 (2006).
119. Yano, T. et al. The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor ?-induced apoptosis. Mol. Cell. Biol. 26, 4474-4488 (2006).
120. Wildey, G. M. & Howe, P. H. Runx1 is a co-activator with FOXO3 to mediate transforming growth factor ? (TGF?)-induced Bim transcription in hepatic cells. J. Biol. Chem. 284, 20227-20239 (2009).
121. Osorio, K. M. et al. Runx1 modulates developmental, but not injury-driven, hair follicle stem cell activation. Development 135, 1059-1068 (2008).
122. Osorio, K. M., Lilja, K. C. & Tumbar, T. Runx1 modulates adult hair follicle stem cell emergence and maintenance from distinct embryonic skin compartments. J. Cell Biol. 193, 235-250 (2011).
123. Gaur, T. et al. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J. Biol. Chem. 280, 33132-33140 (2005).
124. Ito, K. RUNX3 in oncogenic and anti-oncogenic signaling in gastrointestinal cancers. J. Cell Biochem. 112, 1243-1249 (2011).
125. Fijneman, R. J. et al. Runx1 is a tumor suppressor gene in the mouse gastrointestinal tract. Cancer Sci. 103, 593-599 (2012).
126. Licchesi, J. D. et al. Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis 29, 895-904 (2008).
127. Stender, J. D. et al. Genome-wide analysis of estrogen receptor ? DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Mol. Cell. Biol. 30, 3943-3955 (2010).
128. Khalid, O. et al. Modulation of Runx2 activity by estrogen receptor-?: Implications for osteoporosis and breast cancer. Endocrinology 149, 5984-5995 (2008).
129. Chimge, N. O. et al. Regulation of breast cancer metastasis by Runx2 and estrogen signaling: The role of SNAI2. Breast Cancer Res. 13, R127 (2011).
130. Huang, B. et al. RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor ?. Oncogene 31, 527-534 (2012).
131. Cheng, A. S. et al. Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res. 68, 1786-1796 (2008).
132. Junttila, M. R. & Evan, G. I. p53 - a Jack of all trades but master of none. Nature Rev. Cancer 9, 821-829 (2009).
133. Junttila, M. R. et al. Selective activation of p53 mediated tumour suppression in high-grade tumours. Nature 468, 567-571 (2010).
134. Feldser, D. M. et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468, 572-575 (2010).
135. Blyth, K., Cameron, E. R. & Neil, J. C. The RUNX genes: Gain or loss of function in cancer. Nature Rev. Cancer 5, 376-387 (2005).
136. Kilbey, A., Terry, A., Cameron, E. R. & Neil, J. C. Oncogene-induced senescence: An essential role for Runx. Cell Cycle 7, 2333-2340 (2008).
137. Kilbey, A. et al. Runx2 disruption promotes immortalization and confers resistance to oncogene-induced senescence in primary murine fibroblasts. Cancer Res. 67, 11263-11271 (2007). In a similar way to RUNX1, RUNX2 and RUNX3 are shown to induce senescence in primary MEFs. Oncogenic RAS can transform MEFs when Runx2 is deleted.
138. Linggi, B. et al. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14ARF tumor suppressor in acute myeloid leukemia. Nature Med. 8, 743-750 (2002). RUNX1 transcriptionally activates ARF, whereas RUNX1-ETO represses ARF, suggesting that one of the mechanisms of leukaemogenesis is found in the repression of ARF expression by the fusion protein and subsequent inability to stabilize p53.
139. Motoda, L. et al. Runx1 protects hematopoietic stem/progenitor cells from oncogenic insult. Stem Cells 25, 2976-2986 (2007).
140. Zaidi, S. K. et al. Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tumorigenic potential. Proc. Natl Acad. Sci. USA 104, 19861-19866 (2007).
141. Wolyniec, K. et al. RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress. Oncogene 28, 2502-2512 (2009).
142. Masse, I. et al. Functional interplay between p63 and p53 controls RUNX1 function in the transition from proliferation to differentiation in human keratinocytes. Cell Death Dis. 3, e318 (2012).
143. Van Der Deen, M. et al. MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma. J. Biol. Chem. 288, 21307-21319 (2013).
144. Malkin, D. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233-1238 (1990).
145. Kurokawa, M. et al. Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies. Oncogene 12, 883-892 (1996).
146. Wotton, S. F. et al. RUNX1 transformation of primary embryonic fibroblasts is revealed in the absence of p53. Oncogene 23, 5476-5486 (2004).
147. Vaillant, F. et al. A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with myc. Oncogene 18, 7124-7134 (1999).
148. Blyth, K. et al. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Res. 66, 2195-2201 (2006).
149. Satoh, Y. et al. C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells. Leukemia 26, 303-311 (2012).
150. Wu, D., Ozaki, T., Yoshihara, Y., Kubo, N. & Nakagawara, A. Runt-related transcription factor 1 (RUNX1) stimulates tumor suppressor p53 protein in response to DNA damage through complex formation and acetylation. J. Biol. Chem. 288, 1353-1364 (2013).
151. Yamada, C. et al. RUNX3 modulates DNA damage-mediated phosphorylation of tumor suppressor p53 at Ser-15 and acts as a co-activator for p53. J. Biol. Chem. 285, 16693-16703 (2010).
152. Ozaki, T., Wu, D., Sugimoto, H., Nagase, H. & Nakagawara, A. Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage. Cell Death Dis. 4, e610 (2013).
153. Tanaka, Y. et al. Runx3 interacts with DNA repair protein Ku70. Exp. Cell Res. 313, 3251-3260 (2007).
154. Levy, D., Adamovich, Y., Reuven, N. & Shaul, Y. Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. Mol. Cell 29, 350-361 (2008).
155. Levy, D., Reuven, N. & Shaul, Y. A regulatory circuit controlling Itch-mediated p73 degradation by Runx. J. Biol. Chem. 283, 27462-27468 (2008).
156. Wang, C. Q. et al. Disruption of Runx1 and Runx3 leads to bone marrow failure and leukemia predisposition due to transcriptional and DNA repair defects. Cell Rep. 8, 767-782 (2014). RUNX1 and RUNX3 interact with Fanconi anaemia proteins to mediate DNA repair of interstrand crosslinks, suggesting that defective DNA repair could be the mechanism of leukaemogenesis.
157. Chang, S. H. et al. T helper 17 cells play a critical pathogenic role in lung cancer. Proc. Natl Acad. Sci. USA 111, 5664-5669 (2014).
158. Elinav, E. et al. Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms. Nature Rev. Cancer 13, 759-771 (2013).
159. Reis, B. S., Rogoz, A., Costa-Pinto, F. A., Taniuchi, I. & Mucida, D. Mutual expression of the transcription factors Runx3 and ThPOK regulates intestinal CD4+ T cell immunity. Nature Immunol. 14, 271-280 (2013).
160. Brenner, O. et al. Loss of Runx3 function in leukocytes is associated with spontaneously developed colitis and gastric mucosal hyperplasia. Proc. Natl Acad. Sci. USA 101, 16016-16021 (2004).
161. Zhang, F., Meng, G. & Strober, W. Interactions among the transcription factors Runx1, ROR?t and Foxp3 regulate the differentiation of interleukin 17-producing T cells. Nature Immunol. 9, 1297-1306 (2008).
162. Hor, Y. T. et al. A role for RUNX3 in inflammation-induced expression of IL23A in gastric epithelial cells. Cell Rep. 8, 50-58 (2014).
163. Voon, D. C. et al. Runx3 protects gastric epithelial cells against epithelial-mesenchymal transition-induced cellular plasticity and tumorigenicity. Stem Cells 30, 2088-2099 (2012).
164. Chang, T. L. et al. Claudin-1 has tumor suppressive activity and is a direct target of RUNX3 in gastric epithelial cells. Gastroenterology 138, 255-265 (2010).
165. Tanaka, S. et al. Runt-related transcription factor 3 reverses epithelial-mesenchymal transition in hepatocellular carcinoma. Int. J. Cancer 131, 2537-2546 (2012).
166. Inoue, K. et al. The transcription factor Runx3 represses the neurotrophin receptor TrkB during lineage commitment of dorsal root ganglion neurons. J. Biol. Chem. 282, 24175-24184 (2007).
167. Douma, S. et al. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430, 1034-1039 (2004).
168. Zhang, H. Y. et al. RUNX1 and RUNX2 upregulate galectin-3 expression in human pituitary tumors. Endocrine. 35, 101-111 (2009).
169. Lee, S. H., Kim, J., Kim, W. H. & Lee, Y. M. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells. Oncogene 28, 184-194 (2009).
170. Peng, Z. G. et al. Physical and functional interaction of Runt-related protein 1 with hypoxia-inducible factor-1?. Oncogene 27, 839-847 (2008).
171. Lee, S. H., Bae, S. C., Kim, K. W. & Lee, Y. M. RUNX3 inhibits hypoxia-inducible factor-1? protein stability by interacting with prolyl hydroxylases in gastric cancer cells. Oncogene 33,1458-1467 (2013).
172. Lee, S. H. et al. Runx2 protein stabilizes hypoxia-inducible factor-1? through competition with Von Hippel-Lindau protein (pVHL) and stimulates angiogenesis in growth plate hypertrophic chondrocytes. J. Biol. Chem. 287, 14760-14771 (2012).
173. Wheeler, J. C. et al. Distinct in vivo requirements for establishment versus maintenance of transcriptional repression. Nature Genet. 32, 206-210 (2002).
174. Sebe-Pedros, A., De Mendoza, A., Lang, B. F., Degnan, B. M. & Ruiz-Trillo, I. Unexpected repertoire of metazoan transcription factors in the unicellular holozoan Capsaspora owczarzaki. Mol. Biol. Evol. 28, 1241-1254 (2011).
175. Coffman, J. A. Is Runx a linchpin for developmental signaling in metazoans? J. Cell Biochem. 107, 194-202 (2009).
176. Kagoshima, H. et al. The C. elegans RUNX transcription factor RNT-1/MAB-2 is required for asymmetrical cell division of the T blast cell. Dev. Biol. 287, 262-273 (2005).
177. Nimmo, R. Antebi, A. & Woollard, A. mab-2 encodes RNT-1, a C. elegans Runx homologue essential for controlling cell proliferation in a stem cell-like developmental lineage. Development 132, 5043-5054 (2005).
178. Ji, Y. J. et al. RNT-1, the C. elegans homologue of mammalian RUNX transcription factors, regulates body size and male tail development. Dev. Biol. 274, 402-412 (2004).
179. Lee, K., Shim, J., Bae, J., Kim, Y. J. & Lee, J. Stabilization of RNT-1 protein, runt-related transcription factor (RUNX) protein homolog of Caenorhabditis elegans, by oxidative stress through mitogen-activated protein kinase pathway. J. Biol. Chem. 287, 10444-10452 (2012).
180. Robertson, A. J., Coluccio, A., Knowlton, P., Dickey-Sims, C. & Coffman, J. A. Runx expression is mitogenic and mutually linked to Wnt activity in blastula-stage sea urchin embryos. PLoS ONE 3, e3770 (2008).
181. Canon, J. & Banerjee, U. Runt and Lozenge function in Drosophila development. Semin. Cell Dev. Biol. 11, 327-336 (2000).
182. Wildonger, J., Sosinsky, A., Honig, B. & Mann, R. S. Lozenge directly activates argos and klumpfuss to regulate programmed cell death. Genes Dev. 19, 1034-1039 (2005).
183. Terriente-Felix, A. et al. Notch cooperates with Lozenge/Runx to lock haemocytes into a differentiation programme. Development 140, 926-937 (2013).
184. Venkatesh, B. et al. Elephant shark genome provides unique insights into gnathostome evolution. Nature 505, 174-179 (2014).
185. Wang, Q. et al. The CBF? subunit is essential for CBF?2 (AML1) function in vivo. Cell 87, 697-708 (1996).
186. Chen, W. et al. Cbf? deletion in mice recapitulates cleidocranial dysplasia and reveals multiple functions of Cbf? required for skeletal development. Proc. Natl Acad. Sci. USA 111, 8482-8487 (2014).
187. Liu, P. et al. Fusion between transcription factor CBF ?/PEBP2 ? and a myosin heavy chain in acute myeloid leukemia. Science 261, 1041-1044 (1993).
188. Castilla, L. H. et al. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell 87, 687-696 (1996).
189. Castilla, L. H. et al. The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia. Nature Genet. 23, 144-146 (1999).
190. Guo, Y. et al. Structural basis for hijacking CBF-? and CUL5 E3 ligase complex by HIV-1 Vif. Nature 505, 229-233 (2014).
191. Kim, D. Y. et al. CBF? stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression. Mol. Cell 49, 632-644 (2013).
192. Harada, H. et al. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 103, 2316-2324 (2004).
193. Kuo, M. C. et al. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia 23, 1426-1431 (2009).